EGFR and non-small cell lung carcinoma: In non-small cell lung cancer, EGFR inhibitor- resistant gefitinib-treated and the (sensitive) CL-387,785-treated H1975 cells were compared to identify transcriptional changes with EGFR-activating mutations (Kobayashi et al., 2006).